

# Rachelle H Crosbie

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/780333/publications.pdf>

Version: 2024-02-01

28  
papers

1,805  
citations

361413

20  
h-index

501196

28  
g-index

28  
all docs

28  
docs citations

28  
times ranked

2014  
citing authors

#	ARTICLE	IF	CITATIONS
1	Progressive Muscular Dystrophy in $\beta$ -Sarcoglycan-deficient Mice. <i>Journal of Cell Biology</i> , 1998, 142, 1461-1471.	5.2	331
2	Assembly of the Dystrophin-Associated Protein Complex Does Not Require the Dystrophin CooH-Terminal Domain. <i>Journal of Cell Biology</i> , 2000, 150, 1399-1410.	5.2	201
3	Sarcospan, the 25-kDa Transmembrane Component of the Dystrophin-Glycoprotein Complex. <i>Journal of Biological Chemistry</i> , 1997, 272, 31221-31224.	3.4	165
4	Biosynthesis of dystroglycan: processing of a precursor propeptide. <i>FEBS Letters</i> , 2000, 468, 79-83.	2.8	152
5	Membrane Targeting and Stabilization of Sarcospan Is Mediated by the Sarcoglycan Subcomplex. <i>Journal of Cell Biology</i> , 1999, 145, 153-165.	5.2	128
6	Type V Collagen in Scar Tissue Regulates the Size of Scar after Heart Injury. <i>Cell</i> , 2020, 182, 545-562.e23.	28.9	113
7	Loss of sarcolemma nNOS in sarcoglycan-deficient muscle. <i>FASEB Journal</i> , 2002, 16, 1786-1791.	0.5	80
8	Caveolin-3 is not an integral component of the dystrophin glycoprotein complex. <i>FEBS Letters</i> , 1998, 427, 279-282.	2.8	75
9	Hypertrophic response of Duchenne and limb-girdle muscular dystrophies is associated with activation of Akt pathway. <i>Experimental Cell Research</i> , 2006, 312, 2580-2591.	2.6	67
10	Mitochondrial Dysfunction Is an Early Consequence of Partial or Complete Dystrophin Loss in mdx Mice. <i>Frontiers in Physiology</i> , 2020, 11, 690.	2.8	61
11	Myogenic Akt signaling attenuates muscular degeneration, promotes myofiber regeneration and improves muscle function in dystrophin-deficient mdx mice. <i>Human Molecular Genetics</i> , 2011, 20, 1324-1338.	2.9	52
12	Characterization of aquaporin-4 in muscle and muscular dystrophy. <i>FASEB Journal</i> , 2002, 16, 943-949.	0.5	48
13	Sarcospan reduces dystrophic pathology: stabilization of the utrophin-glycoprotein complex. <i>Journal of Cell Biology</i> , 2008, 183, 419-427.	5.2	48
14	Spp1 (osteopontin) promotes TGF $\beta$ 2 processing in fibroblasts of dystrophin-deficient muscles through matrix metalloproteinases. <i>Human Molecular Genetics</i> , 2019, 28, 3431-3442.	2.9	47
15	Myogenic Akt signaling upregulates the utrophin-glycoprotein complex and promotes sarcolemma stability in muscular dystrophy. <i>Human Molecular Genetics</i> , 2009, 18, 318-327.	2.9	42
16	NO vascular control in Duchenne muscular dystrophy. <i>Nature Medicine</i> , 2001, 7, 27-29.	30.7	38
17	Structural and functional analysis of the sarcoglycan-sarcospan subcomplex. <i>Experimental Cell Research</i> , 2007, 313, 639-651.	2.6	26
18	Disrupted mechanical stability of the dystrophin-glycoprotein complex causes severe muscular dystrophy in sarcospan transgenic mice. <i>Journal of Cell Science</i> , 2007, 120, 996-1008.	2.0	25

#	ARTICLE	IF	CITATIONS
19	Direct interaction of Gas11 with microtubules: Implications for the dynein regulatory complex. <i>Cytoskeleton</i> , 2007, 64, 461-473.	4.4	21
20	Expanding the Role of the Dynein Regulatory Complex to Non-Axonemal Functions: Association of GAS11 with the Golgi Apparatus. <i>Traffic</i> , 2006, 7, 538-548.	2.7	20
21	Stabilization of the cardiac sarcolemma by sarcospan rescues DMD-associated cardiomyopathy. <i>JCI Insight</i> , 2019, 4, .	5.0	18
22	Over-expression of Microspan, a novel component of the sarcoplasmic reticulum, causes severe muscle pathology with triad abnormalities. <i>Journal of Muscle Research and Cell Motility</i> , 2006, 27, 545-558.	2.0	13
23	Altered calcium pump and secondary deficiency of $\beta$ -sarcoglycan and microspan in sarcoplasmic reticulum membranes isolated from $\beta$ -sarcoglycan knockout mice. <i>Cell Calcium</i> , 2010, 48, 28-36.	2.4	9
24	Large in-frame 5â€² deletions in DMD associated with mild Duchenne muscular dystrophy: Two case reports and a review of the literature. <i>Neuromuscular Disorders</i> , 2019, 29, 863-873.	0.6	6
25	Development of a high-throughput screen to identify small molecule enhancers of sarcospan for the treatment of Duchenne muscular dystrophy. <i>Skeletal Muscle</i> , 2019, 9, 32.	4.2	6
26	Sarcospan increases laminin-binding capacity of $\beta$ -dystroglycan to ameliorate DMD independent of $\alpha$ -Galgt2. <i>Human Molecular Genetics</i> , 2022, 31, 718-732.	2.9	6
27	Loss of sarcospan exacerbates pathology in $\alpha$ -mdx mice, but does not affect utrophin amelioration of disease. <i>Human Molecular Genetics</i> , 2021, 30, 149-159.	2.9	4
28	High-throughput screening identifies modulators of sarcospan that stabilize muscle cells and exhibit activity in the mouse model of Duchenne muscular dystrophy. <i>Skeletal Muscle</i> , 2020, 10, 26.	4.2	3